Environmental

Low Direct Environmental Footprint: As a clinical-stage biotechnology company with no commercial manufacturing or marketed products, ProMIS Neurosciences currently has a limited direct environmental impact compared to peers with large-scale production facilities.

Sustainability Reporting Gaps: There is no evidence of formal sustainability disclosures, climate risk assessments, or environmental targets in recent filings or press releases, which is below best practice for sector leaders.

Pipeline-Driven Future Impact: If ProMIS advances to late-stage development or commercialization, environmental risks could increase due to clinical supply chain scaling and potential manufacturing, but these are not yet material.

ProMIS Neurosciences’ environmental risk profile is currently moderate, reflecting its early-stage operations and lack of manufacturing. However, the absence of sustainability reporting and climate strategy is a gap relative to best-in-class biotech peers.

Social

Clinical Trial Safety and Patient Focus: The PRECISE-AD Phase 1b trial for PMN310 has shown a favorable safety profile with no cases of amyloid-related imaging abnormalities (ARIA), a key patient safety concern in Alzheimer’s therapies.

Innovative Approach to Unmet Needs: ProMIS targets toxic protein oligomers in neurodegenerative diseases, addressing significant unmet medical needs and potentially improving patient outcomes over existing therapies.

Stakeholder Engagement and Transparency: The company actively communicates with investors and the public through conference participation, webcasts, and regular updates on clinical progress, supporting transparency and stakeholder trust.

ProMIS demonstrates strong social performance through its patient-centric clinical development, focus on high unmet needs, and transparent stakeholder engagement. Continued safety and efficacy in trials will be critical to maintaining this position.

Governance

Board Strengthening and Expertise: The recent appointment of Dr. Slanix Paul Alex, an experienced healthcare investor, enhances board expertise in capital markets and biopharma innovation, aligning with strategic needs.

Regulatory Compliance and Nasdaq Listing: The company is proactively addressing Nasdaq minimum bid price compliance through a reverse stock split, demonstrating responsiveness to listing requirements and investor protections.

Capital Discipline and Financial Oversight: ProMIS maintains low leverage and has raised capital to support R&D, but persistent operating losses and reliance on external funding highlight ongoing financial risks typical for clinical-stage biotech firms.

Governance is moderate, with recent board enhancements and regulatory compliance actions. However, financial sustainability remains a key risk until clinical milestones are achieved and commercial revenues are established.

Overall Score

ProMIS Neurosciences exhibits moderate overall ESG performance. Social factors are strong due to patient safety and innovation, while governance is supported by board improvements and compliance actions. Environmental risks are currently limited but lack proactive management. The company’s ESG profile will depend on its ability to maintain clinical progress, strengthen sustainability practices, and achieve financial resilience.